National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
JAMA Netw Open. 2024 Jul 1;7(7):e2422558. doi: 10.1001/jamanetworkopen.2024.22558.
Limited evidence supports the association between low-density lipoprotein cholesterol (LDL-C) and mortality across different atherosclerotic cardiovascular disease (ASCVD) risk stratifications.
To explore the associations between LDL-C levels and mortality and to identify the optimal ranges of LDL-C with the lowest risk of mortality in populations with diverse ASCVD risk profiles.
DESIGN, SETTING, AND PARTICIPANTS: The ChinaHEART project is a prospective cohort study that recruited residents aged 35 to 75 years from 31 provinces in mainland China between November 2014 and December 2022. Participants were categorized into low-risk, primary prevention, and secondary prevention cohorts on the basis of their medical history and ASCVD risk. Data analysis was performed from December 2022 to October 2023.
The primary end point was all-cause mortality, and secondary end points included cause-specific mortality. Mortality data were collected from the National Mortality Surveillance System and Vital Registration. The association between LDL-C levels and mortality was assessed by using Cox proportional hazard regression models with various adjusted variables.
A total of 4 379 252 individuals were recruited, and 3 789 025 (2 271 699 women [60.0%]; mean [SD] age, 56.1 [10.0] years) were included in the current study. The median (IQR) LDL-C concentration was 93.1 (70.9-117.3) mg/dL overall at baseline. During a median (IQR) follow-up of 4.6 (3.1-5.8) years, 92 888 deaths were recorded, including 38 627 cardiovascular deaths. The association between LDL-C concentration and all-cause or cardiovascular disease (CVD) mortality was U-shaped in both the low-risk cohort (2 838 354 participants) and the primary prevention cohort (829 567 participants), whereas it was J-shaped in the secondary prevention cohort (121 104 participants). The LDL-C levels corresponding to the lowest CVD mortality were 117.8 mg/dL in the low-risk group, 106.0 mg/dL in the primary prevention cohort, and 55.8 mg/dL in the secondary prevention cohort. The LDL-C concentration associated with the lowest all-cause mortality (90.9 mg/dL vs 117.0 mg/dL) and CVD mortality (87 mg/dL vs 114.6 mg/dL) were both lower in individuals with diabetes than in individuals without diabetes in the overall cohort.
This study found that the association between LDL-C and mortality varied among different ASCVD risk cohorts, suggesting that stricter lipid control targets may be needed for individuals with higher ASCVD risk and those with diabetes.
目前仅有有限的证据支持低密度脂蛋白胆固醇(LDL-C)与不同动脉粥样硬化性心血管疾病(ASCVD)风险分层之间的死亡率相关。
本研究旨在探讨 LDL-C 水平与死亡率之间的关联,并确定不同 ASCVD 风险特征人群中 LDL-C 水平与最低死亡率相关的最佳范围。
设计、地点和参与者:中国心脏研究(ChinaHEART)是一项前瞻性队列研究,于 2014 年 11 月至 2022 年 12 月期间从中国大陆 31 个省招募了年龄在 35 至 75 岁之间的居民。根据病史和 ASCVD 风险,将参与者分为低危、初级预防和二级预防队列。数据分析于 2022 年 12 月至 2023 年 10 月进行。
主要终点是全因死亡率,次要终点包括特定原因死亡率。死亡率数据来自国家死亡率监测系统和生命登记处。采用 Cox 比例风险回归模型,根据不同的调整变量评估 LDL-C 水平与死亡率之间的关联。
共招募了 4379252 名参与者,其中 3789025 名(2271699 名女性[60.0%];平均[标准差]年龄 56.1[10.0]岁)纳入了本研究。基线时,总体 LDL-C 浓度的中位数(IQR)为 93.1(70.9-117.3)mg/dL。在中位数(IQR)4.6(3.1-5.8)年的随访期间,记录了 92888 例死亡,包括 38627 例心血管疾病死亡。LDL-C 浓度与全因或心血管疾病(CVD)死亡率之间的关联在低危队列(2838354 名参与者)和初级预防队列(829567 名参与者)中呈 U 形,而在二级预防队列(121104 名参与者)中呈 J 形。在低危组,LDL-C 水平与最低 CVD 死亡率相关的最佳值为 117.8mg/dL,在初级预防组为 106.0mg/dL,在二级预防组为 55.8mg/dL。在整个队列中,患有糖尿病的个体 LDL-C 浓度与最低全因死亡率(90.9mg/dL 比 117.0mg/dL)和 CVD 死亡率(87mg/dL 比 114.6mg/dL)相关的最佳值均低于无糖尿病个体。
本研究发现,LDL-C 与死亡率之间的关联在不同的 ASCVD 风险队列中存在差异,这表明对于 ASCVD 风险较高的个体和患有糖尿病的个体,可能需要更严格的血脂控制目标。